Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release US FDA Accepts Wockhardt s New Drug Application for Breakthrough Antibiotic Zaynich .
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The US FDA has accepted Wockhardt's New Drug Application (NDA) for Zaynich, the company's breakthrough antibiotic. FDA acceptance means the application is complete enough for a substantive review, bringing the drug one step closer to potential US market approval. Zaynich has been developed as a treatment for serious drug-resistant bacterial infections, an area with high unmet medical need. No specific timeline for the FDA decision or projected revenue impact has been disclosed in this filing.
Positive for shareholders as it advances Wockhardt's pipeline toward a potentially lucrative US market launch, though this is regulatory acceptance, not final approval, so commercial upside remains contingent on the FDA's eventual decision.